# Regulatory Hurdles for Humanoid Healthcare: US (FDA) vs. EU (MDR)

## General Challenges for Both Regions:

• **Novelty and Precedent**: Humanoid caregivers represent a novel category requiring immense complexity in establishing new pathways. This includes the need for potential pilot programs, extensive stakeholder engagement, and even legislative changes. Regulators will need to establish clear pathways and potentially adapt existing frameworks through unprecedented collaboration between multiple agencies & international bodies **-** hindering streamlined approvals.

• **Safety and Efficacy**: Demonstrating that the humanoid is safe for interaction with vulnerable populations and effective in its caregiving tasks is paramount. This includes mechanical safety, software reliability, and preventing unintended harm, specifically: - **Cybersecurity Risks**: Humanoids represent potential targets when connected to healthcare systems, requiring robust protection against malicious attacks that could compromise patient safety or data integrity. - **Risk Management**: Rigorous processes such as FMEA (Failure Modes & Effects Analysis) and Fault Tree Analysis must be implemented to identify and mitigate potential failure scenarios. - **Usability & Human Factors**: Critical assessment of how humanoids interact with diverse user groups (e.g., elderly, cognitively impaired, physically disabled) for both safety and efficacy, ensuring accessibility and appropriate response to varied user capabilities.

• **Human-Robot Interaction (HRI)**: Special attention is needed for how the robot interacts with people, especially in an autonomous or semi-autonomous capacity. This includes aspects like communication, physical contact, and emotional impact. Extensive psychological and sociological studies are required to quantify and regulate the emotional impact on patients, caregivers, and healthcare staff.

• **Ethical Considerations**: Beyond regulation, ethical discussions around autonomy, accountability, potential for dependency, and the role of robots in personal care will be crucial. This significantly expanded area includes: - **Data Bias**: The risk of AI algorithms perpetuating biases present in training data, potentially leading to

discriminatory care delivery or exacerbating health inequalities. - **Accountability Chain**: The legal responsibility in the case of errors is complex, involving manufacturer, hospital, physician, Patient / Caregiver & the distributed nature of AI -**Informed Consent**: The challenge of obtaining truly informed consent for care delivered by autonomous or semi-autonomous systems, particularly when patients may not understand the tech's capabilities limitations & there is a critical need for simplified communication, education & training strategies.

- **Post-Market Surveillance**: Continuous monitoring of the device once it's on the market to detect any unforeseen issues, adverse events, or performance degradation. This requires proactive elements including trending adverse events, regular safety updates, and Post-Market Clinical Follow-up (PMCF) studies to ensure ongoing safety and effectiveness throughout the device lifecycle.

## United States (FDA - Food and Drug Administration):

### 1. Medical Device Classification:

- **SaMD (Software as a Medical Device)**: The software driving the humanoid's caregiving functions (e.g., monitoring, reminding, assisting) will almost certainly be classified as SaMD, requiring its own comprehensive regulatory review with specific documentation and validation requirements.

- **Hardware Classification**: The physical robot itself will be classified as a medical device based on its intended use (e.g., monitoring vital signs, assisting with mobility, dispensing medication). The intended use drives classification, and any diagnostic, treatment, or significant monitoring function will push it to higher classes (Class II or III), requiring more rigorous review (510(k) premarket notification or PMA premarket approval).

- **Combination Products**: Humanoids dispensing medication may be classified as "combination products" (device + drug), adding significant regulatory complexity requiring coordination between CDRH (Center for Devices and Radiological Health) and CDER (Center for Drug Evaluation and Research), potentially extending approval timelines and costs.

### 2. FDA Medical Device Regulations:

• **21 CFR Part 820 (Quality System Regulation)**: Manufacturers must establish and maintain a quality system that covers design, production, and distribution of medical devices.

• **Premarket Notification (510(k)) or PMA**: For truly novel, high-risk humanoids, the PMA (Premarket Approval) pathway is far more likely than 510(k) due to the difficulty of demonstrating "substantial equivalence" to existing devices. The PMA pathway is significantly longer, costlier, and more rigorous, often requiring extensive clinical trials and comprehensive safety and effectiveness data, can take years & cost $10's millions.

### 3. Standards:

• **ISO 13485**: While not directly an FDA regulation, compliance with this international standard for medical device quality management systems is highly recommended and often a de facto requirement for FDA clearance. Non-compliance requires strong scientific and regulatory justification.

• **IEC 60601 Series**: Applicable for electrical medical equipment, this series covers general requirements for basic safety and essential performance. Recognition by FDA does not guarantee acceptance; non-compliance requires robust justification.

• **IEC 80601-2-78**: This specific standard focuses on "Medical robots for rehabilitation, assessment, compensation or alleviation of an impairment" – highly relevant for a caregiving humanoid.

• **ANSI/AAMI Standards**: Various American National Standards Institute/Association for the Advancement of Medical Instrumentation standards may apply depending on specific functionalities.

## European Union (MDR - Medical Device Regulation):

**Important Note**: Medical devices are regulated under the Medical Device Regulation (MDR) (EU 2017/745), not by the European Medicines Agency (EMA), which primarily deals with medicines.

## 1. MDR (Medical Device Regulation) (EU 2017/745):

This is the overarching regulation for medical devices in the EU.

- **CE Marking**: All medical devices placed on the EU market must bear a CE Mark, indicating conformity with the MDR.

- **Classification Rules**: The MDR has detailed classification rules (Class I, IIa, IIb, III) based on risk and invasiveness. A humanoid caregiver with advanced functions would likely fall into Class IIa, IIb, or III.

- **Notified Body**: For Class IIa, IIb, and III devices, involvement of a Notified Body is critical and mandatory for conformity assessment and CE Marking. This represents a significant bottleneck and cost factor, as Notified Bodies have limited capacity leading to delays of months and charge substantial fees for their services.

- **General Safety and Performance Requirements (GSPR)**: Devices must meet comprehensive GSPRs outlined in Annex I of the MDR.

- **Clinical Evaluation**: Demonstrating clinical safety and performance through a rigorous clinical evaluation process.

- **Technical Documentation**: Comprehensive documentation covering design, manufacturing, risk management, and post-market surveillance.

- **Post-Market Surveillance (PMS) and PMCF**: Stringent MDR requirements for ongoing clinical data collection throughout the device's lifecycle, including systematic collection and analysis of post-market clinical data.

- **Person Responsible for Regulatory Compliance (PRRC)**: Mandatory role for manufacturers under MDR, requiring specific qualifications including a degree in law, medicine, pharmacy, engineering, or other relevant scientific discipline, plus one year of regulatory affairs **-** to ensure continuous compliance & key contact for authorities.

## 2. SaMD (Software as a Medical Device):

The MDR explicitly includes software as a medical device and outlines its specific classification rules and requirements.

### 3. Standards:

• **ISO 13485**: Essential for demonstrating compliance with the MDR's quality management system requirements.

• **EN IEC 60601 Series**: Harmonized European versions of the IEC 60601 standards for electrical medical equipment.

• **EN IEC 80601-2-78**: The European harmonized version of the medical robot safety standard.

• **Other Harmonized Standards**: Various other EN (European Norm) standards will apply for specific aspects like usability, cybersecurity, and biocompatibility (if relevant).

## Privacy and Security Considerations (US HIPAA/HITECH vs. EU GDPR):

Both regions have stringent data privacy laws that are critical for humanoid caregivers, as they will likely collect sensitive personal health information (PHI).

### United States:

**1. HIPAA (Health Insurance Portability and Accountability Act) & HITECH Act (Health Information Technology for Economic and Clinical Health Act):**

• **Protected Health Information (PHI)**: Any individually identifiable health information collected, stored, transmitted, or used by the humanoid (e.g., vital signs, medication adherence, activity levels, verbal interactions about health) would be considered PHI. Also Biometric data would be collected.

• **Covered Entities & Business Associates**: If the humanoid is part of a healthcare provider's system or if the manufacturer/developer acts as a service provider handling PHI on behalf of a covered entity, they would need to be HIPAA compliant (as a business associate).

• **Business Associate Agreement (BAA)**: Mandatory requirement for a BAA between a Covered Entity and any Business Associate handling PHI, establishing specific

obligations and liability frameworks.

- **Security Rule**: Requires administrative, physical, and technical safeguards to protect electronic PHI (ePHI). This includes encryption, access controls, audit trails, and data integrity measures.

- **Privacy Rule**: Governs the use and disclosure of PHI, requiring patient consent for many uses and disclosures, and providing patients with rights over their health information.

- **Breach Notification Rule**: Mandates reporting of breaches of unsecured PHI with serious implications including substantial costs, reputational damage, and specific timelines for notification (60 days to HHS, immediate notification to affected individuals for breaches affecting 500+ individuals).

## European Union:

### 1. GDPR (General Data Protection Regulation) (EU 2016/679):

- **Personal Data & Special Categories of Data**: Health data is explicitly defined as a "special category" of personal data, requiring higher levels of protection.

- **Lawfulness of Processing**: Processing of health data usually requires explicit consent from the individual, though other potential legal bases exist (e.g., legitimate interest, vital interests), with consent often preferred for health data due to its higher legal certainty & the sensitive nature of health data.

- **Data Protection Officer (DPO)**: Certain companies must appoint a DPO, particularly those processing large amounts of special category data or conducting systematic monitoring.

- **Data Protection by Design and Default**: Privacy and security measures must be built into the system from the ground up, not added as an afterthought.

- **Data Protection Impact Assessments (DPIA)**: Likely required due to the high-risk nature of processing sensitive health data with new technology.

- **Technical and Organizational Measures**: Strong security measures (encryption, pseudonymization, access controls, regular testing) are mandatory to protect personal data.

• **Data Subject Rights**: Individuals have extensive rights, including access, rectification, erasure, and restriction of processing.

• **Right to Be Forgotten/Erasure**: Presents technical challenges for fully erasing data and significant impact on continuously learning AI models, which may need to be retrained after data deletion.

• **Cross-Border Data Transfers**: Strict rules apply if data is transferred outside the EU/EEA, with historical and ongoing complexities including the invalidation of Privacy Shield and current reliance on Standard Contractual Clauses and adequacy decisions.

## Regional Approaches to AI Regulation: Diverging Philosophies and Implementation Strategies

The regulatory landscape for artificial intelligence technologies, including those integrated into medical devices like humanoid caregivers, varies significantly across major jurisdictions, reflecting fundamentally different philosophical approaches to innovation and risk management.

### European Union (EU AI Act):

The European Union has adopted a comprehensive, risk-based regulatory framework through the EU AI Act, which categorizes AI systems into four risk tiers:

• **Unacceptable Risk (Prohibited)**: AI systems that pose unacceptable risks to safety, livelihoods, and rights are banned outright. The implications of "unacceptable risk" classifications may significantly impact the future evolution of humanoid AI, particularly in areas involving social scoring or real-time biometric identification.

• **High Risk (Strict Requirements)**: AI applications used in healthcare, critical infrastructure, and law enforcement require rigorous conformity assessments, CE marking, and ongoing monitoring.

• **Limited Risk (Transparency Obligations)**: AI systems that interact with humans must clearly disclose their artificial nature.

• **Minimal Risk (No Specific Obligations)**: Low-risk AI applications with minimal regulatory requirements.

**Key Requirements for High-Risk AI Systems:** • Detailed documentation and technical specifications • Implementation of human oversight mechanisms • Regular audits and compliance assessments • Algorithmic transparency and bias testing • Explainability requirements for AI-driven decision-making processes

For humanoid healthcare devices, this means additional layers of compliance beyond traditional medical device regulations under the MDR.

## United States (Sector-Specific Approach):

The United States has pursued a more sector-specific and innovation-friendly approach, relying primarily on existing regulatory frameworks adapted for AI applications rather than creating overarching AI-specific legislation. However, "innovation-friendly" also means less certainty and a more fragmented regulatory landscape compared to the EU.

**FDA Guidance on AI/ML-Based Medical Devices:** • Predetermined change control plans for continuous learning algorithms • Software as a Medical Device (SaMD) classification and requirements • Focus on post-market surveillance and real-world performance monitoring • Emphasis on manufacturer responsibility for self-regulation

**Key Differences from EU Approach:** • No comprehensive risk categorization system • Greater flexibility in implementation • Prioritizes rapid innovation and market deployment • Less prescriptive regulatory requirements

## Global Compliance Challenges:

This regulatory divergence creates significant compliance challenges for global manufacturers of AI-enabled medical devices:

• **Dual Compliance Requirements**: Companies must navigate both EU's prescriptive requirements and US's more flexible regulatory environment.

• **System Variations**: Different versions of AI systems may be needed to meet varying transparency, explainability, and human oversight requirements across jurisdictions. This implies potentially different product versions (not just paperwork) for different markets, significantly impacting R&D, manufacturing, and maintenance strategies.

• **Cost Implications**: Compliance costs extend beyond mere regulatory fees to include development of jurisdiction-specific features and documentation.

• **Innovation Impact**: The pace of innovation and global deployment strategies for advanced healthcare robotics may be affected by these regulatory differences.

• **Market Access**: Timing of product launches may vary significantly between regions due to different approval processes and requirements.

# Critical Content for SaMD Dossier Submissions: EU (MDR) vs. US (FDA)

This section provides a comprehensive checklist of essential documents and data components that are absolutely critical for successful SaMD dossier submissions for humanoid caregiver devices in both jurisdictions.

## European Union (MDR) SaMD Dossier Requirements:

**General Dossier Structure/Format:**

• **Technical Documentation File (TDF)**: Comprehensive documentation package as per Annex II and III of MDR • **Declaration of Conformity**: Formal declaration that the device meets all applicable requirements • **CE Marking Documentation**: Evidence supporting CE marking application • **Notified Body Assessment Report**: For Class IIa, IIb, and III devices

**Software-Specific Documentation:**

• **Software Requirements Specification (SRS)**: Detailed functional and performance requirements • **Software Design and Architecture Documentation**: System architecture, data flow diagrams, interface specifications • **Verification and Validation (V&V) Documentation**: - Software test plans and protocols - Test execution reports and results - Traceability matrices linking requirements to tests - Software validation summary report • **Risk Management File (ISO 14971)**: Software-specific risk analysis, risk control measures, and residual risk evaluation • **Cybersecurity Documentation**: - Threat modeling and vulnerability assessments - Security testing reports and penetration testing results - Patch management and update procedures - Cybersecurity incident response plan • **AI/ML Specific Documentation**: - Algorithm

description and mathematical models - Training data documentation (sources, quality, bias analysis) - Model validation and performance metrics - Explainability and interpretability reports - Continuous learning and model update procedures

**Clinical Evidence:**

• **Clinical Evaluation Report (CER)**: Comprehensive analysis of clinical data demonstrating safety and performance • **Clinical Investigation Plan and Reports**: If clinical studies are conducted • **Post-Market Clinical Follow-up (PMCF) Plan**: Strategy for ongoing clinical data collection • **Real-World Evidence (RWE) Strategy**: Plan for collecting and analyzing real-world performance data • **Literature Review**: Systematic review of relevant clinical literature • **Clinical Risk-Benefit Analysis**: Evaluation of clinical benefits versus risks

**Quality Management System (QMS) Evidence:**

• **ISO 13485 Certification**: Evidence of compliant quality management system • **Design Control Procedures**: Documentation of design and development processes • **Production and Process Controls**: Manufacturing and quality control procedures • **Post-Market Surveillance Procedures**: Systems for monitoring device performance post-launch • **Corrective and Preventive Action (CAPA) Procedures**: Process for addressing quality issues

**Usability Engineering:**

• **Usability Engineering File (IEC 62366-1)**: Complete usability engineering documentation • **Usability Validation Reports**: Evidence of successful usability testing with representative users • **Human Factors Analysis**: Assessment of human-device interaction risks and mitigations • **Use Error Analysis**: Identification and mitigation of potential use errors

**Labeling and Instructions for Use (IFU):**

• **Draft Labels and Packaging**: Proposed labeling with all required information • **Instructions for Use (IFU)**: Comprehensive user instructions including: - Intended use and indications - Contraindications and warnings - Safety precautions and limitations - Installation and setup procedures - Maintenance and troubleshooting guidance

**Data Privacy Compliance:**

• **Data Protection Impact Assessment (DPIA)**: Mandatory assessment for high-risk data processing • **Data Protection Officer (DPO) Appointment**: Evidence of DPO designation if required • **Data Flow Maps**: Visual representation of personal data processing activities • **Privacy by Design Documentation**: Evidence of privacy considerations in system design • **Data Subject Rights Procedures**: Processes for handling individual rights requests • **Cross-Border Transfer Mechanisms**: Legal basis for international data transfers

## United States (FDA) SaMD Dossier Requirements:

**General Dossier Structure/Format:**

• **Q-Submission (Pre-Submission)**: Optional but recommended pre-submission meeting documentation • **510(k) Premarket Notification** or **PMA Application**: Depending on device classification • **Device Description and Intended Use**: Clear statement of device purpose and target population • **Predicate Device Comparison**: For 510(k) submissions, detailed comparison with legally marketed device

**Software-Specific Documentation:**

• **Software Requirements Specification**: Detailed functional and performance requirements • **Software Design and Architecture**: System design documentation including data flow and interfaces • **Verification and Validation (V&V) Documentation**: - Software verification protocols and reports - Software validation testing documentation - Traceability analysis linking requirements to verification activities • **Risk Management Documentation**: Software risk analysis per ISO 14971 • **Cybersecurity Documentation**: - Cybersecurity risk assessment - Security controls and testing documentation - Software bill of materials (SBOM) - Vulnerability management procedures • **AI/ML Specific Documentation**: - Algorithm description and performance characteristics - Training data documentation and bias analysis - Model validation and clinical validation studies - Predetermined Change Control Plan (PCCP) for continuous learning algorithms - Algorithm change protocol for locked algorithms

**Clinical Evidence:**

• **Clinical Study Reports**: Detailed reports of pivotal clinical studies • **Clinical Study Protocols**: Study design and methodology documentation • **Statistical Analysis Plans**: Pre-specified statistical methods and endpoints • **Real-World Evidence (RWE) Studies**: Post-market performance data if applicable • **Clinical Risk Assessment**: Evaluation of clinical risks and benefits • **Endpoint Justification**: Rationale for selected clinical endpoints

**Quality Management System (QMS) Evidence:**

• **ISO 13485 Compliance Evidence**: Documentation of quality management system • **Design Controls (21 CFR 820.30)**: Evidence of design control implementation • **Production and Process Controls**: Manufacturing quality procedures • **Post-Market Surveillance Plan**: Strategy for ongoing device monitoring • **Medical Device Reporting (MDR) Procedures**: Process for adverse event reporting

**Usability Engineering:**

• **Human Factors Validation Study**: Comprehensive usability testing with representative users • **Use-Related Risk Analysis**: Assessment of use errors and risk mitigations • **Usability Engineering Process**: Documentation of human factors engineering activities • **User Interface Design Rationale**: Justification for interface design decisions

**Labeling and Instructions for Use (IFU):**

• **Proposed Labeling**: Draft labels meeting FDA requirements including: - Intended use statement - Indications for use - Contraindications and warnings - Precautions and limitations • **Instructions for Use**: Comprehensive user documentation • **Risk Communication**: Clear communication of device risks and limitations

**Data Privacy Compliance:**

• **Business Associate Agreement (BAA) Template**: Standard agreement for HIPAA compliance • **HIPAA Security Rule Compliance**: Documentation of administrative, physical, and technical safeguards • **Privacy Impact Assessment**: Evaluation of privacy risks and mitigations • **Data Breach Response Plan**: Procedures for handling potential data breaches • **Audit Trail Documentation**: Systems for tracking data access and modifications

### Key Differences in Submission Requirements:

• **Clinical Evidence Approach**: EU requires Clinical Evaluation Report with literature review and clinical data synthesis, while US typically requires controlled clinical studies with statistical analysis • **Notified Body vs. FDA Review**: EU requires third-party Notified Body assessment for higher-class devices, while FDA conducts direct regulatory review • **Privacy Framework**: EU emphasizes GDPR compliance with DPIA requirements, while US focuses on HIPAA compliance with BAA frameworks • **AI/ML Documentation**: EU AI Act requires additional algorithmic transparency and bias testing, while US emphasizes predetermined change control plans for adaptive algorithms • **Post-Market Requirements**: EU has more stringent PMCF requirements, while US emphasizes MDR (Medical Device Reporting) and post-market studies. Expect the Development Cost to be another differentiator (less expensive in US, Asia vs EU).

## Conclusion

Navigating the regulatory landscape for humanoid healthcare is an endeavor of immense complexity, requiring a deeply integrated and forward-thinking compliance strategy. While this document effectively outlines the key regulatory frameworks and common challenges in both the US and EU, success hinges on a profound appreciation for the nuances of medical device classification, the rigorous demands of clinical evidence generation for novel technologies, and the ever-evolving nature of AI and data privacy regulations. Proactive engagement with regulatory bodies, coupled with a robust quality management system and a realistic timeline for extensive clinical validation, will be paramount in bringing these transformative caregiving solutions safely and effectively to market. The general purpose humanoids are arriving in the home, we must find a way to protect Patients against their misuse as unofficial Caregivers.

## Disclaimer

The information provided in this document is for general informational purposes only and does not constitute legal, medical, or regulatory advice. Regulatory pathways for novel technologies, particularly those involving artificial intelligence, robotics, and healthcare, are complex and subject to change. Readers should consult with qualified legal, regulatory, and medical professionals to address specific situations and ensure compliance with all applicable laws and regulations in their respective jurisdictions. The projections, timelines, and financial estimates presented are illustrative and based on assumptions that may not materialize.

**Slide 1**: Conceptual Regulatory and Pilot Timeline Plans for Europe

**Cost Implications:** Expect the cost of bringing compliant Humanoids to market to be another differentiator, with potentially **lower development and compliance costs in the US and Asia compared to the EU** due to the EU's more prescriptive requirements, longer approval timelines (especially for higher-risk devices), and significant Notified Body fees.




**Slide 2:** To include US and EU, then a **Dual Track** Regulatory Strategy is Required

**Slide 3:** The success of Humanoid Healthcare in resolving the Human Caregiver crisis demands substantial time and investment. To achieve this, a powerful consortium of sponsors and strategic partnerships, potentially bolstered by national governmental health services, is imperative. While the regulatory hurdles are formidable, we must overcome them. This is the only path to mitigate the immense legal liability stemming from the high risk of misuse of general-purpose Home Humanoids as unoffical caregivers, making this initiative an absolute necessity.


# **Slide 1 MORE DETAILS**: Conceptual Regulatory and Pilot Timeline Plans for Europe

| **EU Workstreams** | | |
|---|---|---|
| | | |
| **Longer description per line item in Gantt chart** | **Challenge** | **Mitigation** |
| **Phase 1: Foundation & Planning** | | |
| *Regulatory Landscape & Public Consultation - This initial stage involves thoroughly understanding the existing and evolving regulatory frameworks within the European Union that pertain to medical devices, particularly Software as a Medical Device (SaMD) and advanced robotics. It includes identifying key directives, guidance documents, and standards such as the Medical Device Regulation (MDR) (EU 2017/745). Public consultation means actively engaging with various stakeholders including national competent authorities, Notified Bodies, industry associations, patient advocacy groups, and ethical committees to gather feedback, clarify interpretations, and build consensus on the regulatory approach for novel humanoid healthcare devices.* | Diverse interpretations of the MDR across different EU member states can lead to inconsistencies and uncertainty. Engaging with a wide array of stakeholders, each with their own interests and perspectives, requires significant coordination and consensus-building efforts. The sheer volume and complexity of existing regulations, combined with the novelty of humanoid technology, make it difficult to identify all applicable requirements upfront. | Implement a robust regulatory intelligence gathering process to monitor national and EU-level guidance updates. Establish a dedicated cross-functional team responsible for stakeholder engagement, utilizing a structured communication plan. Proactively participate in industry working groups and public consultations to influence regulatory development and gain insights. Seek early "scientific advice" or "pre-submission meetings" with key national competent authorities to clarify specific requirements. |
| **Phase 2: Pilot Development & Initial Documentation** | | |
| *Defining Tracking and 'Humanoid' (Regulatory) - This critical step involves precisely defining the intended use, scope, and specific functionalities of the humanoid caregiver device in a way that aligns with regulatory classifications. It requires a detailed technical description of the robot's hardware and software components, its operational environment, and the target patient population. The term "Humanoid" itself is novel in a regulatory context, necessitating a clear definition of its boundaries, capabilities, and the specific medical purpose it serves, which will ultimately dictate its classification under the MDR (e.g., Class IIa, IIb, or III). This phase also includes initiating the core documentation required for the Technical Documentation File.* | The absence of specific regulatory precedents for "humanoid" devices makes classification challenging and highly dependent on the "intended use." Overly broad or vague definitions can lead to higher risk classifications and more stringent regulatory requirements, while overly narrow definitions might limit market potential. The inherent complexity and multi-functionality of humanoids can make it difficult to precisely delineate their medical purpose versus general wellness features. | Conduct a thorough risk assessment based on potential harms and intended use to guide classification. Develop a detailed "Intended Use Statement" that is precise, justifiable, and focuses on the medical purpose. Engage in early dialogue with a prospective Notified Body to gain their opinion on the proposed classification and intended use, potentially through a "classification query." Clearly distinguish between medical functions (regulated) and non-medical functions (not regulated) of the humanoid. |
| **Phase 3: Pilot Deployment & RWE Collection** | | |
| *Liaison with Patients, PAGs (VoP) & KOLs for Advocacy - This phase focuses on gathering real-world evidence (RWE) through pilot deployments of the humanoid caregiver. It involves close collaboration with patients (Voice of Patient - VoP), Patient Advocacy Groups (PAGs), and Key Opinion Leaders (KOLs) such as leading clinicians, researchers, and healthcare administrators. The goal is to obtain user feedback on the device's usability, safety, efficacy, and overall acceptance in real-world settings. This advocacy also helps to build a strong case for the device's value proposition and address ethical concerns, informing both product development and regulatory submissions.* | Ensuring that the pilot studies are ethically conducted, particularly with vulnerable populations (e.g., elderly, cognitively impaired), presents significant challenges. Collecting high-quality, relevant RWE in diverse settings can be complex and resource-intensive. Gaining authentic and unbiased feedback from patients and advocates requires careful design of engagement strategies to avoid influencing responses. | Develop a robust RWE strategy and protocol that is approved by relevant ethics committees. Engage with PAGs early in the study design to ensure patient perspectives are integrated. Collaborate with KOLs to leverage their expertise in clinical trial design and to ensure the RWE collected is scientifically sound and addresses regulatory needs. Implement transparent communication channels and feedback mechanisms for patients and advocacy groups. |
| **Phase 4: Regulatory Submission & Review** | | |
| *Liaison Affiliates, EMA, Local Authorities, Stakeholders - This stage involves the formal submission of the comprehensive Technical Documentation File to a Notified Body (for CE Marking) or other relevant authorities, and potentially to the European Medicines Agency (EMA) if classified as a combination product or requiring specific software (SaMD) review. "Liaison affiliates" refers to internal or external teams responsible for coordinating the submission across different functional areas and potentially across different countries. Ongoing communication and negotiation with the assigned Notified Body and other stakeholders are crucial during the review period to address questions, provide additional information, and resolve any identified deficiencies.* | Managing the submission process and subsequent dialogue with a Notified Body can be a significant bottleneck due to their limited capacity and high workload. Coordinating responses to complex questions that may span technical, clinical, and quality aspects requires seamless internal collaboration. Disagreements or misinterpretations with the Notified Body can lead to delays and require extensive back-and-forth communication, potentially impacting timelines. | Appoint a highly experienced Person Responsible for Regulatory Compliance (PRRC) to oversee the submission. Maintain consistent and clear communication with the Notified Body throughout the review process, proactively addressing potential issues. Prepare comprehensive and well-organized documentation to minimize queries. Establish a dedicated internal team to rapidly respond to Notified Body questions, ensuring accuracy and completeness. |
| **Phase 5: Prepare Go To Market, scale to first countries** | | |
| *Post-Market Surveillance (Ongoing) - This is a continuous process after the device has received CE Marking and is on the market. It involves actively monitoring the device's performance, safety, and effectiveness in real-world use. This includes collecting data on adverse events, near misses, user feedback, and complaints. Rigorous analysis of this data is required to identify any unforeseen risks, trends, or areas for improvement. This phase also includes activities like Post-Market Clinical Follow-up (PMCF) studies, trending adverse events, and implementing regular safety updates, all to ensure ongoing compliance with MDR requirements throughout the device's lifecycle.* | The MDR places extremely stringent and resource-intensive requirements on Post-Market Surveillance (PMS) and PMCF, demanding continuous data collection and analysis. Detecting and reporting adverse events in a timely manner across multiple EU countries, with varying reporting requirements, is complex. Adapting to evolving patient needs or new clinical insights based on PMS data requires agile product development and regulatory update processes. | Implement a robust, automated PMS system capable of collecting, analyzing, and reporting data from diverse sources. Establish clear internal procedures for adverse event reporting and investigation, ensuring compliance with national and EU requirements. Allocate sufficient resources for PMCF studies, incorporating feedback loops into design and development processes for continuous improvement. Regularly review and update the risk management file based on PMS data. |

Strategic Planning Foundation | Early Stage Regulatory Plans | Medical | Regulatory | Commercial

# **Slide 1 MORE DETAILS**: Conceptual Regulatory and Pilot Timeline Plans for US

| **US Workstreams - likely quicker due to Innovation first** | | |
|---|---|---|
| **Longer description per line item in Gantt chart** | **Challenge** | **Mitigation** |
| **Phase 1: Foundation & Planning** | | |
| *Regulatory Landscape & Public Consultation - This phase involves gaining a deep understanding of the US regulatory environment for medical devices, particularly those classified as SaMD, and novel robotic technologies. This includes familiarizing oneself with FDA regulations such as 21 CFR Part 820 (Quality System Regulation) and relevant FDA guidance documents on software, cybersecurity, and AI/ML-based medical devices. "Public consultation" in the US context often refers to reviewing publicly available FDA guidance, participating in public workshops, and engaging with industry groups (e.g., AdvaMed) rather than formal public comment periods, to interpret requirements and identify precedents for novel technologies.* | The US regulatory framework, while "innovation-friendly," can be perceived as less prescriptive than the EU's, leading to uncertainty in interpretation. Identifying directly applicable precedents for a highly novel device like a humanoid caregiver is often difficult, requiring extrapolation from existing guidance. The need to balance rapid innovation with ensuring patient safety can create tensions between developmental speed and regulatory thoroughness. | Proactively utilize FDA's Q-submission program (e.g., Pre-Submission meetings) to seek early feedback on regulatory strategy, classification, and study design. Engage regulatory consultants with specific expertise in novel medical devices and AI/ML. Continuously monitor FDA announcements, workshops, and guidance updates relevant to AI and robotics in healthcare. |
| **Phase 2: Pilot Development & Initial Documentation** | | |
| *Defining Tracking and 'Humanoid' (Regulatory) - This step involves precisely articulating the intended use of the humanoid caregiver device, which is the primary determinant of its regulatory classification by the FDA (e.g., Class I, II, or III, leading to 510(k) or PMA pathways). It requires a detailed technical description of the hardware, software (including any AI/ML components), and user interface. Defining "humanoid" in a regulatory sense means identifying its specific medical functions that classify it as a medical device, distinct from general wellness or consumer applications. This phase also initiates the preparation of core documentation, including design controls and risk management files.* | The novelty of humanoid medical devices means there are few, if any, direct FDA predicate devices, making a 510(k) "substantial equivalence" claim challenging and potentially pushing the device towards the more rigorous PMA pathway. Precisely defining the "intended use" for a multi-functional device to avoid unintended higher classifications or to ensure comprehensive coverage of its benefits is a delicate task. Differentiating between "software as a medical device" (SaMD) and software that is part of a medical device (SiMD) is crucial for the regulatory pathway. | Conduct a thorough risk assessment based on the device's functional capabilities and potential patient impact. Draft a detailed "Intended Use Statement" and discuss it with the FDA via a Pre-Submission meeting to get early feedback on classification. Clearly document all design controls and traceability to requirements, anticipating the rigorous review of a PMA or complex 510(k). Engage human factors engineers early to refine the device's interaction with users. |
| **Phase 3: Pilot Deployment & RWE Collection** | | |
| *Liaison with Patients, PAGs (VoP) & KOLs for Advocacy - This phase involves conducting pilot studies and clinical trials to gather robust clinical evidence, including Real-World Evidence (RWE), to demonstrate the safety and effectiveness of the humanoid caregiver. Collaboration with patients (Voice of Patient - VoP), Patient Advocacy Groups (PAGs), and Key Opinion Leaders (KOLs) is essential. This engagement helps to inform clinical trial design, collect patient-centric outcomes, and gather feedback on the device's utility and acceptance. Advocacy efforts from these groups can support regulatory submissions by highlighting unmet clinical needs and the device's value proposition.* | Designing clinical trials that adequately demonstrate safety and efficacy for a novel, multi-functional device like a humanoid can be complex and expensive. Integrating RWE into traditional regulatory pathways (510(k)/PMA) requires careful justification and robust methodologies to ensure data quality and relevance. Securing diverse patient cohorts for trials and managing ethical considerations, especially for vulnerable populations, adds to the complexity. | Develop a comprehensive clinical development plan that includes early feasibility studies, pivotal trials, and a strategy for RWE integration, discussing this plan with the FDA early (e.g., Pre-Submission). Engage with patient advocacy groups to incorporate patient perspectives into outcome measures and trial design. Collaborate with KOLs to develop robust clinical protocols and identify appropriate study sites. |
| **Phase 4: Regulatory Submission & Review** | | |
| *Liaison Affiliates, EMA, Local Authorities, Stakeholders - This stage entails the formal submission of regulatory applications to the FDA (e.g., 510(k) Premarket Notification or PMA Premarket Approval). "Liaison affiliates" involve internal teams (e.g., R&D, Clinical, Quality, Regulatory Affairs) that coordinate the compilation and review of the submission dossier. During the FDA's review cycle, there is continuous communication, including responding to Additional Information (AI) requests, participating in review meetings, and clarifying any data or technical aspects. This engagement is crucial to navigate the review process efficiently and effectively.* | Responding to FDA Additional Information (AI) requests within strict timelines requires significant internal resources and rapid turnaround, especially for complex questions about novel technology. Navigating the potentially long and costly PMA pathway, which involves extensive clinical data and manufacturing controls, is a major hurdle. Aligning the data and documentation to FDA's specific format and content requirements can be challenging. | Appoint a highly experienced regulatory affairs lead with a strong track record of FDA submissions for novel devices. Implement an internal system for tracking and responding to FDA communications promptly and accurately. Conduct internal mock FDA reviews to identify potential weaknesses in the submission before actual filing. Proactively prepare comprehensive answers to anticipated questions based on FDA guidance and previous interactions. |
| **Phase 5: Prepare Go To Market, scale to first countries** | | |
| *Post-Market Surveillance (Ongoing) - This continuous process begins once the device has received FDA clearance or approval and is commercialized. It involves systematically collecting and analyzing data on the device's performance, safety, and effectiveness in real-world use. This includes monitoring for adverse events (e.g., through MedWatch reports), user complaints, and performing trend analysis. The FDA expects manufacturers to have a robust Post-Market Surveillance (PMS) plan in place to detect unforeseen issues, ensure continued compliance with regulations, and facilitate continuous product improvement throughout its lifecycle. This also includes managing software updates and ensuring cybersecurity vigilance.* | Establishing and maintaining a robust PMS system that effectively captures, analyzes, and reports adverse events and user feedback across a broad user base can be complex. Ensuring timely reporting of adverse events to the FDA (e.g., within 30 days for serious events) requires efficient internal processes. Adapting to evolving FDA guidance on PMS, particularly for AI/ML-based devices with continuous learning capabilities, requires ongoing vigilance. | Develop and implement a comprehensive PMS plan that aligns with FDA requirements and best practices for SaMD. Utilize automated systems for collecting and analyzing real-world performance data. Establish clear internal procedures for adverse event reporting and investigation, ensuring compliance with FDA's MedWatch system. Maintain continuous cybersecurity monitoring and a plan for rapid response to vulnerabilities. |

Strategic Planning Foundation | Early Stage Regulatory Plans | Medical | Regulatory | Commercial

*Basel, 14th Sept 2025*

*Andrew Squire, Founder* PatientCentricCare.AI *&* HumanoidHealthcare.AI